Bright Minds Biosciences Inc.
DRUG
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.13% | 35.04% | 13.20% | -14.31% | -35.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 407.17% | 143.71% | 0.15% | -61.79% | -63.94% |
| Operating Income | -407.17% | -143.71% | -0.15% | 61.79% | 63.94% |
| Income Before Tax | -325.40% | -142.00% | 37.78% | 84.14% | 62.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -325.40% | -142.00% | 37.78% | 84.14% | 62.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -325.40% | -142.00% | 37.78% | 84.14% | 62.23% |
| EBIT | -407.17% | -143.71% | -0.15% | 61.79% | 63.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -143.02% | -39.00% | 62.73% | 86.38% | 65.53% |
| Normalized Basic EPS | -142.97% | -39.00% | 62.74% | 86.38% | 65.52% |
| EPS Diluted | -142.18% | -38.41% | 62.74% | 86.25% | 65.36% |
| Normalized Diluted EPS | -143.07% | -39.07% | 62.69% | 86.34% | 65.52% |
| Average Basic Shares Outstanding | 59.59% | 49.69% | 39.69% | 28.95% | 15.59% |
| Average Diluted Shares Outstanding | 62.35% | 52.57% | 42.70% | 32.09% | 15.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |